PLX Stock Overview
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Protalix BioTherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.66 |
| 52 Week High | US$1.90 |
| 52 Week Low | US$0.82 |
| Beta | 0.67 |
| 11 Month Change | 56.60% |
| 3 Month Change | 71.54% |
| 1 Year Change | 17.73% |
| 33 Year Change | 66.00% |
| 5 Year Change | -41.96% |
| Change since IPO | -99.39% |
Recent News & Updates
Shareholder Returns
| PLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 17.7% | -6.5% | -1.0% |
| 1Y | 17.7% | 14.6% | 30.3% |
Return vs Industry: PLX exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: PLX underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PLX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 208 | Dror Bashan | www.protalix.com |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases.
Protalix BioTherapeutics, Inc. Fundamentals Summary
| PLX fundamental statistics | |
|---|---|
| Market cap | US$124.44m |
| Earnings (TTM) | -US$9.61m |
| Revenue (TTM) | US$45.67m |
2.7x
P/S Ratio-12.7x
P/E RatioIs PLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLX income statement (TTM) | |
|---|---|
| Revenue | US$45.67m |
| Cost of Revenue | US$29.29m |
| Gross Profit | US$16.38m |
| Other Expenses | US$25.98m |
| Earnings | -US$9.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 35.86% |
| Net Profit Margin | -21.03% |
| Debt/Equity Ratio | 0% |
How did PLX perform over the long term?
See historical performance and comparison